tiprankstipranks
Icosavax announces interim results from IVX-A12 trial
PremiumThe FlyIcosavax announces interim results from IVX-A12 trial
7M ago
Icosavax to be acquired by AstraZeneca for $15.00 per share in cash, CVR
PremiumThe Fly
Icosavax to be acquired by AstraZeneca for $15.00 per share in cash, CVR
7M ago
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
PremiumPress Releases
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
7M ago
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
PremiumPress ReleasesIcosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
9M ago
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
PremiumPress Releases
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
10M ago
Icosavax reports Q2 EPS (59c), consensus (60c)
PremiumThe Fly
Icosavax reports Q2 EPS (59c), consensus (60c)
11M ago
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
PremiumPress ReleasesIcosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
1y ago
Icosavax reports Q4 EPS (59c), consensus (59c)
PremiumThe Fly
Icosavax reports Q4 EPS (59c), consensus (59c)
1y ago
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
PremiumPress Releases
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100